Clinical operations note: what-buying-a-robotic-surgery-system-taught-me-about-globus-medical-and-118

Last February, I sat across from an orthopedic surgeon and a lab director in the hospital's purchasing office. The board had approved $2.8 million for three capital purchases: a robotic surgery system, a chemistry analyzer, and a flow cytometer. As the procurement manager who has tracked every invoice for the past six years, I thought I knew how to compare prices. I was wrong within three hours.

How the Process Started

The board gave us a deadline: February 16, because the capital budget had to be locked in. That was a compressed timeline. I normally like three months for an RFP, with vendor demos and site visits. We had five weeks, and each department wanted its own favorite product. The surgeon wanted a robotic surgery system that could handle spine cases. The lab director wanted a chemistry analyzer and a flow cytometer. All three were justifiable, but I had to fit them into the same budget.

I made the first mistake before I even opened the quotes. I knew the lab director had a costing model from a previous equipment purchase, but I thought, 'What are the odds that a $20,000 price gap would change the result?' The odds caught up with me about an hour later.

What the Lab Director Taught Me About Chemistry Analyzers

A chemistry analyzer is the machine that automates the common blood tests—think glucose, electrolytes, liver enzymes, and kidney function panels. We needed ours because our core lab volume had grown about 9% year over year. I asked for quotes from three vendors. The lowest capital price was $98,000. The next one was $118,000. I was ready to negotiate with the lower-priced vendor until the lab director added a column for reagents. The $98,000 analyzer required a proprietary reagent system and a monthly carrying fee. The $118,000 one accepted open reagents from a separate supplier and had a lower per-test cost. On 450,000 tests a year, the reagent difference was $47,000 annually. The $20,000 lower capital price turned into a $215,000 higher five-year cost.

I almost argued with her. I'm glad I didn't. That one comparison taught me more about medical equipment purchasing than any negotiation I had run until then.

The Real Question Behind Flow Cytometry

Then came the flow cytometer. The lab director asked, 'What is flow cytometry?' I gave a textbook answer: it's a method that passes individual cells through a laser beam to count, sort, and measure cell size, granularity, and fluorescence. It matters for diagnosing leukemia, lymphoma, and immune deficiencies. She nodded and asked the question that really mattered from a budget perspective: 'What does the service contract cost per test?'

One vendor's flow cytometer had a lower purchase price but a service plan at 11% of the equipment cost each year. Another vendor's price was higher, but the service plan was included for two years and the per-test reagent cost was lower. Over five years, the difference between the two was only $12,000. That is a good example of why you cannot compare two quotes by looking at the first page. The details are in the calibration beads, the cleaning solution, and the labor needed for quality controls.

The Robotic Surgery System Quote That Made Me Pause

The robotic surgery system was the largest purchase, so I set aside extra time. I started by looking at the regulatory landscape: as of January 2025, the FDA's 510(k) database (accessed January 2025, if you want to check) lists multiple cleared robotic platforms for orthopedic use. I'm not qualified to compare clinical outcomes. From a procurement standpoint, I only cared about what the regulators allowed, what the codes covered, and how a platform would hold its value over five years.

That is where Globus Medical kept showing up. The company is often mentioned alongside ExcelsiusGPS, their robotic surgery system designed for navigation in spine procedures. I also kept seeing 'Globus Medical Nevro' in my searches. I'm not going to pretend I understand every partnership detail, and I don't know if the two companies will ever be formally combined. But from a buying perspective, seeing a vendor's name next to another technology tells me to ask about modularity. I want to know if today's robot can work with tomorrow's tools, or if I'm buying an island.

What I didn't expect was an address issue. Our accounts payable system contained a Globus Medical Memphis TN address on one vendor registration form. I assumed the company had moved from its Audubon, Pennsylvania headquarters. It hadn't. Globus Medical is headquartered in Audubon, Pennsylvania. The Memphis TN address was probably a remittance or regional office, but I couldn't be sure until I called and asked. That one phone call probably saved us from sending a signed agreement to the wrong office and waiting another week for it to be forwarded.

The Five-Year Cost Model That Changed My Mind

Here is the part that still bothers me. The robotic surgery system with the lowest base quote was $1.42 million. Its installation fee was extra, instruments were priced per case, and the service contract went up by 4% after year two. Over five years, the total was $2.05 million. The Globus Medical quote started at $1.68 million, but it included installation, training, and a set of instruments, and the service contract was flat for the first three years. Five-year total: $1.74 million. The quote that looked cheaper by $260,000 on the first line would have cost us $310,000 more over the time we owned it.

I should mention that I built the model with help from our biomedical engineering team. They caught costs I would have missed: the camera cleaning supplies, the navigation tracker replacements, the software update fee that was listed separately for the low-priced system. They also pointed out that the low-priced system needed a dedicated power line in the OR, which was another $14,000 of construction. None of those costs were hidden in a malicious way; they were simply not in the base quote.

Their reimbursement team also answered our billing department's CPT mapping question in writing, which is exactly the kind of support that has no line item but makes a CFO's life easier.

Why I Still Second-Guessed Myself

Even after the numbers were clear, I kept second-guessing the decision. What if I missed a footnoted service exclusion? What if the lower-priced platform had lower per-case instruments that our model didn't capture? I didn't relax until I requested written confirmation from Globus Medical that their quoted service plan covered hardware and software updates for the 36-month contract. That confirmation took nine days to arrive. Those nine days were stressful.

We also uncovered a process gap during this purchase. Our procurement team did not have a formal checklist for comparing recurring costs in capital equipment bids. The third time I saw a dock fee appear on a quote as a separate line item, I finally built an ownership cost worksheet for future RFPs. I should have done that years earlier. It would have prevented at least one past mistake that I won't relitigate here.

The Lesson for Any Procurement Decision

Would I make the same decision again? Yes. But not just because the five-year calculation favored the higher capital price. I learned that value over price means looking at what the vendor is really asking you to defer. A low base price is often a deferral, not a discount. The line item that shows up later was always in the deal; you just weren't looking at the right part of the contract.

For anyone in a similar position, I'd say this: ask the users what they plan to run on the equipment before you ask for a price. Let them explain the chemistry analyzer and the flow cytometer and the robotic surgery system in their own words. Then bring in biomedical engineering. Check every address on the registration forms, and do not ignore a 'Globus Medical Memphis TN address' just because it doesn't match the headquarters. Call. Verify. Build a five-year model. The lowest capital price is not the decision; the lowest total cost is.